KOL Views: Sizing up looming anti-CGRP turf war in light of new data, possible approval

It is shaping up to be a busy week for anti-CGRP mAbs. Amgen and Novartis are expecting an approval from the FDA for Aimovig (erenumab) on May 17 and Eli Lilly just revealed top-line results from a pair of Phase III trials of its galcanezumab in cluster headaches.

To provide FirstWord readers with rapid feedback on where Aimovig goes from here and the impact of the galcanezumab readouts, we are hosting an expert call with a key opinion leader (KOL) on May 18.

Key topics that will be discussed during the call include, among other things… feedback on Aimovig’s (prospective) label and any surprises contained therein; thoughts on how quickly it will be adopted and where it will be used most frequently in chronic and episodic patients; how does fremanezumab’s quarterly dosing schedule look relative to monthly Aimovig and/or galcanezumab; how impressive is galcanezumab’s success in episodic cluster headaches and how much of a disappointment was the readout in chronic cluster headaches; how likely is galcanezumab to be approved for cluster headaches and how much of an advantage would this be for the product?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the commercial prospects for anti-CGRP mAbs.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.